Clinical Trial Detail

NCT ID NCT02743611
Title Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bellicum Pharmaceuticals
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Rimiducid

BPX-701

Age Groups: senior adult

No variant requirements are available.